HUE028910T2 - Phosphoinositide 3-kinase inhibitor with a zinc binding moiety - Google Patents
Phosphoinositide 3-kinase inhibitor with a zinc binding moiety Download PDFInfo
- Publication number
- HUE028910T2 HUE028910T2 HUE12764605A HUE12764605A HUE028910T2 HU E028910 T2 HUE028910 T2 HU E028910T2 HU E12764605 A HUE12764605 A HU E12764605A HU E12764605 A HUE12764605 A HU E12764605A HU E028910 T2 HUE028910 T2 HU E028910T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- cancer
- tumor
- disease
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470849P | 2011-04-01 | 2011-04-01 | |
| US201161559489P | 2011-11-14 | 2011-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028910T2 true HUE028910T2 (en) | 2017-01-30 |
Family
ID=46931927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12764605A HUE028910T2 (en) | 2011-04-01 | 2012-03-30 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| HUE16166266A HUE045041T2 (hu) | 2011-04-01 | 2012-03-30 | Cink-kötõ lánccal rendelkezõ foszfoinozitid 3-kináz inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16166266A HUE045041T2 (hu) | 2011-04-01 | 2012-03-30 | Cink-kötõ lánccal rendelkezõ foszfoinozitid 3-kináz inhibitor |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US8710219B2 (OSRAM) |
| EP (2) | EP3111938B1 (OSRAM) |
| JP (3) | JP6242331B2 (OSRAM) |
| KR (2) | KR20180108848A (OSRAM) |
| CN (2) | CN103582483B (OSRAM) |
| AU (1) | AU2012236367B2 (OSRAM) |
| BR (1) | BR112013025340B1 (OSRAM) |
| CA (1) | CA2830822C (OSRAM) |
| CL (1) | CL2013002823A1 (OSRAM) |
| CY (2) | CY1117785T1 (OSRAM) |
| DK (2) | DK2694075T3 (OSRAM) |
| EA (1) | EA022434B9 (OSRAM) |
| ES (2) | ES2577982T3 (OSRAM) |
| HR (2) | HRP20160545T1 (OSRAM) |
| HU (2) | HUE028910T2 (OSRAM) |
| IL (2) | IL228588A (OSRAM) |
| LT (1) | LT3111938T (OSRAM) |
| ME (2) | ME03523B (OSRAM) |
| MX (1) | MX340577B (OSRAM) |
| PE (1) | PE20141382A1 (OSRAM) |
| PL (2) | PL2694075T3 (OSRAM) |
| PT (2) | PT2694075T (OSRAM) |
| RS (2) | RS54903B1 (OSRAM) |
| SG (2) | SG193563A1 (OSRAM) |
| SI (2) | SI3111938T1 (OSRAM) |
| SM (2) | SMT201900435T1 (OSRAM) |
| TW (1) | TWI571469B (OSRAM) |
| WO (1) | WO2012135571A1 (OSRAM) |
| ZA (2) | ZA201307082B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA024252B1 (ru) | 2009-01-08 | 2016-08-31 | Кьюрис, Инк. | Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой |
| HUE028910T2 (en) | 2011-04-01 | 2017-01-30 | Curis Inc | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| DK2780338T3 (en) | 2011-11-14 | 2016-12-19 | Ignyta Inc | Uracil AS AXL- AND C-MET kinase inhibitors |
| CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
| WO2016169417A1 (zh) * | 2015-04-21 | 2016-10-27 | 成都金瑞长青生物科技有限公司 | 嘌呤基-n-羟基嘧啶甲酰胺衍生物及其制备方法和用途 |
| CN109476710B (zh) * | 2016-07-19 | 2021-11-23 | 国立植物基因组研究所 | 抗真菌病原体的新蛋白质 |
| WO2018085342A1 (en) * | 2016-11-02 | 2018-05-11 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| WO2019090331A1 (en) * | 2017-11-06 | 2019-05-09 | Cold Spring Harbor Laboratory | Method and compositions for forming a copper-containing complex and uses thereof |
| WO2020055840A1 (en) | 2018-09-11 | 2020-03-19 | Curis Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| WO2023212574A1 (en) * | 2022-04-26 | 2023-11-02 | Olivia Szu Hsieh Lee Nakaya | Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| WO2001083456A1 (en) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| EP1485348B1 (en) | 2002-03-13 | 2008-06-11 | Janssen Pharmaceutica N.V. | Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| ES2347544T3 (es) | 2002-03-13 | 2010-11-02 | Janssen Pharmaceutica Nv | Inhibidores de histona-desacetilasas. |
| AU2003218738B2 (en) | 2002-03-13 | 2009-01-08 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| KR20040094672A (ko) | 2002-03-13 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| KR101074462B1 (ko) | 2003-01-29 | 2011-10-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 티에노피리미딘 화합물 및 그 용도 |
| US8227636B2 (en) * | 2004-04-05 | 2012-07-24 | Merck Hdac Research, Llc | Histone deacetylase inhibitor prodrugs |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| EP1806347A4 (en) | 2004-10-08 | 2009-07-01 | Astellas Pharma Inc | PYRIMIDINE DERIVATIVES FUSED WITH AN AROMATIC RING |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| CA2605272C (en) | 2005-05-18 | 2013-12-10 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| EP1979328B1 (en) | 2006-01-19 | 2012-12-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| DK1979326T3 (da) | 2006-01-19 | 2013-01-07 | Janssen Pharmaceutica Nv | Pyridin- og pyrimidinderivater som inhibitorer af histondeacetylase |
| EP1981871B1 (en) | 2006-01-19 | 2011-12-28 | Janssen Pharmaceutica N.V. | Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase |
| KR101402474B1 (ko) * | 2006-04-26 | 2014-06-19 | 제넨테크, 인크. | 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물 |
| EP2041139B1 (en) | 2006-04-26 | 2011-11-09 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
| BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
| WO2007131364A1 (en) | 2006-05-16 | 2007-11-22 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| MX2009002585A (es) | 2006-09-11 | 2009-08-24 | Curis Inc | Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc. |
| WO2008033746A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US7928136B2 (en) | 2006-09-11 | 2011-04-19 | Curis, Inc. | Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety |
| WO2008033747A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| WO2008033745A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| CN103275067B (zh) | 2006-10-28 | 2015-09-02 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| KR101507182B1 (ko) | 2006-12-07 | 2015-03-30 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 |
| TWI499420B (zh) | 2006-12-07 | 2015-09-11 | Hoffmann La Roche | 肌醇磷脂３-激酶抑制劑化合物及使用方法 |
| EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| JP2010522163A (ja) | 2007-03-20 | 2010-07-01 | キュリス，インコーポレイテッド | 亜鉛結合部位を含むＲａｆキナーゼインヒビター |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| CA2699202C (en) | 2007-09-12 | 2016-09-27 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| WO2009058895A1 (en) | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
| WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
| EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| US8196911B2 (en) | 2008-10-27 | 2012-06-12 | Honda Motor Co., Ltd. | Adjustable rate subframe mount |
| EA024252B1 (ru) * | 2009-01-08 | 2016-08-31 | Кьюрис, Инк. | Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| AU2010224125B2 (en) | 2009-03-12 | 2015-05-14 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| ES2609767T3 (es) | 2009-10-12 | 2017-04-24 | F. Hoffmann-La Roche Ag | Combinaciones de un inhibidor de PI3K y un inhibidor de MEK |
| EP2557923A4 (en) * | 2010-04-16 | 2013-10-23 | Curis Inc | TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS |
| HUE028910T2 (en) * | 2011-04-01 | 2017-01-30 | Curis Inc | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
| US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| BR122022000334B1 (pt) | 2011-08-01 | 2023-03-21 | Genentech, Inc | Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek |
| CN107735104B (zh) | 2015-06-25 | 2022-05-03 | 免疫医疗公司 | 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善 |
| WO2018085342A1 (en) * | 2016-11-02 | 2018-05-11 | Curis, Inc. | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
-
2012
- 2012-03-30 HU HUE12764605A patent/HUE028910T2/en unknown
- 2012-03-30 RS RS20160457A patent/RS54903B1/sr unknown
- 2012-03-30 SM SM20190435T patent/SMT201900435T1/it unknown
- 2012-03-30 AU AU2012236367A patent/AU2012236367B2/en active Active
- 2012-03-30 MX MX2013011132A patent/MX340577B/es active IP Right Grant
- 2012-03-30 DK DK12764605.7T patent/DK2694075T3/en active
- 2012-03-30 PT PT127646057T patent/PT2694075T/pt unknown
- 2012-03-30 SG SG2013070883A patent/SG193563A1/en unknown
- 2012-03-30 SI SI201231625T patent/SI3111938T1/sl unknown
- 2012-03-30 HR HRP20160545TT patent/HRP20160545T1/hr unknown
- 2012-03-30 ME MEP-2019-179A patent/ME03523B/me unknown
- 2012-03-30 SG SG10201602569RA patent/SG10201602569RA/en unknown
- 2012-03-30 CN CN201280026400.9A patent/CN103582483B/zh active Active
- 2012-03-30 PL PL12764605.7T patent/PL2694075T3/pl unknown
- 2012-03-30 KR KR1020187026847A patent/KR20180108848A/ko not_active Ceased
- 2012-03-30 HU HUE16166266A patent/HUE045041T2/hu unknown
- 2012-03-30 SI SI201230597A patent/SI2694075T1/sl unknown
- 2012-03-30 CN CN201610034817.XA patent/CN105461736B/zh active Active
- 2012-03-30 TW TW101111283A patent/TWI571469B/zh active
- 2012-03-30 DK DK16166266.3T patent/DK3111938T3/da active
- 2012-03-30 EP EP16166266.3A patent/EP3111938B1/en active Active
- 2012-03-30 PE PE2013002160A patent/PE20141382A1/es active IP Right Grant
- 2012-03-30 ME MEP-2016-116A patent/ME02451B/me unknown
- 2012-03-30 RS RSP20190842 patent/RS59219B1/sr unknown
- 2012-03-30 KR KR1020137028748A patent/KR101902325B1/ko active Active
- 2012-03-30 WO PCT/US2012/031361 patent/WO2012135571A1/en not_active Ceased
- 2012-03-30 ES ES12764605.7T patent/ES2577982T3/es active Active
- 2012-03-30 CA CA2830822A patent/CA2830822C/en active Active
- 2012-03-30 PT PT16166266T patent/PT3111938T/pt unknown
- 2012-03-30 BR BR112013025340-1A patent/BR112013025340B1/pt active IP Right Grant
- 2012-03-30 EP EP12764605.7A patent/EP2694075B1/en active Active
- 2012-03-30 PL PL16166266T patent/PL3111938T3/pl unknown
- 2012-03-30 LT LTEP16166266.3T patent/LT3111938T/lt unknown
- 2012-03-30 EA EA201301114A patent/EA022434B9/ru unknown
- 2012-03-30 US US13/435,062 patent/US8710219B2/en active Active
- 2012-03-30 ES ES16166266T patent/ES2733128T3/es active Active
- 2012-03-30 JP JP2014502821A patent/JP6242331B2/ja active Active
-
2013
- 2013-09-19 ZA ZA2013/07082A patent/ZA201307082B/en unknown
- 2013-09-29 IL IL228588A patent/IL228588A/en active IP Right Grant
- 2013-09-30 CL CL2013002823A patent/CL2013002823A1/es unknown
-
2014
- 2014-03-05 US US14/197,769 patent/US9249156B2/en active Active
- 2014-08-21 ZA ZA2014/06167A patent/ZA201406167B/en unknown
-
2015
- 2015-12-28 US US14/979,887 patent/US9657032B2/en active Active
-
2016
- 2016-06-16 SM SM201600179T patent/SMT201600179B/it unknown
- 2016-07-14 CY CY20161100683T patent/CY1117785T1/el unknown
- 2016-08-08 JP JP2016155625A patent/JP6275784B2/ja active Active
- 2016-10-30 IL IL248597A patent/IL248597B/en active IP Right Grant
-
2017
- 2017-04-25 US US15/496,318 patent/US10111864B2/en active Active
-
2018
- 2018-01-10 JP JP2018001910A patent/JP2018052987A/ja not_active Withdrawn
- 2018-10-03 US US16/150,845 patent/US10543197B2/en active Active
-
2019
- 2019-06-17 HR HRP20191091TT patent/HRP20191091T1/hr unknown
- 2019-07-17 CY CY20191100760T patent/CY1121825T1/el unknown
-
2020
- 2020-01-07 US US16/736,081 patent/US11135205B2/en active Active
-
2021
- 2021-09-09 US US17/470,410 patent/US11654136B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11654136B2 (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| HK1232775B (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| HK1232775A1 (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| HK1194969B (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| AU2014280913A1 (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| NZ705039B2 (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| NZ615586B2 (en) | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |